CDSCO Panel Approves Novartis Protocol Amendment Proposal for Ruxolitinib study Dr. Divya Colin4 Jan 2025 5:45 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol...
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children, young adults with spinal muscular atrophy Ruchika Sharma31 Dec 2024 4:16 PM ISTBasel: Novartis has announced positive topline results from the Phase III STEER study. This pivotal study assessed the efficacy and safety of...
CDSCO Panel Approves Novartis Protocol Amendment Proposal for Ianalumab Study Dr. Divya Colin23 Dec 2024 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has approved the drug major...
Sanofi appoints Jean-Paul Kress as Independent Director Ruchika Sharma21 Dec 2024 12:30 PM ISTParis: Sanofi has announced the appointment of Jean-Paul Kress as an Independent Director, effective January 1, 2025. Jean-Paul Kress will...
US Appeals Court decision favors MSN Pharma in Novartis heart drug Entresto generic dispute Ruchika Sharma9 Dec 2024 10:00 AM ISTNovartis suffered a legal setback on Wednesday as the company failed to persuade a U.S. appeals court to halt MSN Pharmaceuticals' proposed generic of...
Novartis bolsters Neuroscience pipeline with in-licensing of PTC518 for Huntington's disease Ruchika Sharma3 Dec 2024 1:30 PM ISTBasel: Novartis has announced that it has entered into a global license and collaboration agreement with PTC Therapeutics for PTC518.PTC518 is an...
Novartis Kisqali gets European Commission nod in patients with HR+/HER2-early breast cancer at high risk of recurrence Ruchika Sharma28 Nov 2024 12:59 PM ISTBasel: Novartis has announced that the European Commission (EC) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI)...
Novartis Healthcare gets CDSCO Panel nod to study Iptacopan Dr. Divya Colin24 Nov 2024 5:45 PM ISTNew Delhi: The drug major Novartis Healthcare has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
Despite Pluvicto, MorphoSys Setbacks, Novartis Raises 2028 Sales Growth Outlook to 6% Farhat Nasim24 Nov 2024 10:30 AM ISTFrankfrut: Novartis raised its medium-term sales guidance on Thursday to 6 percent annual growth through 2028, driven by momentum of launched...
Eli Lilly's Experimental Drug Muvalaplin Lowers Inherited Cholesterol by Up to 86 percent Farhat Nasim20 Nov 2024 1:05 PM ISTRuth Gimeno, Lilly's group vice president for diabetes and metabolic research, said Eli Lilly is weighing next steps for advancing to late stage...
Ratio enters license, collaboration agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate Ruchika Sharma19 Nov 2024 1:30 PM ISTBoston: Ratio Therapeutics Inc, has entered into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG, a subsidiary...
CDSCO Panel Approves Novartis's Protocol Amendment Proposal to Study Ianalumab Dr. Divya Colin1 Nov 2024 5:45 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
